Date: 2016-04-21
Type of information: Construction of new premises
Compound: Novo Nordisk's facilities in Chartres
Company: Novo Nordisk (Denmark)
Therapeutic area: Metabolic diseases
Type agreement: construction of new premises
Action mechanism:
Disease: diabetes
Details: * On April 21, 2016, Novo Nordisk announced that it plans to invest more than 100 million euros in production facilities at its site in Chartres, France. The expansions will help Novo Nordisk meet the increasing worldwide demand for its diabetes medicines. The new facilities will be built on Novo Nordisk's existing 31,000 m2 site in Chartres, which produces a range of the company's insulin products as well as FlexPen®, the world's most widely used insulin injection device. The products are exported to more than 40 countries all over the world. Novo Nordisk has invested 300 million euros in France over the past 15 years and today employs 1,100 employees at the site. The planned expansion is estimated to create around 250 new jobs once the facilities are fully operational within three to four years. In addition to the 1,100 employees in Chartres, Novo Nordisk employs 300 people in its affiliate in Paris, which is responsible for the company's medical, regulatory and commercial activities in France.
Financial terms:
Latest news:
